SCHEMBL30438339

SCHEMBL30438339

O=S(=O)(NC(c1ccc(F)cc1)C(F)(F)F)c1ccn2ncnc2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 1/20 0.38
PDPK1 O15530 1/20 0.37
MAPK1 P28482 1/20 0.35
TNIK Q9UKE5 1/20 0.34
ALOX5AP P20292 5/20 0.33
FEN1 P39748 5/20 0.33
MOGAT2 Q3SYC2 1/20 0.32
PIK3CD O00329 1/20 0.32
KIT P10721 2/20 0.32
NR3C1 P04150 1/20 0.32
PGR P06401 1/20 0.32
SCN1A P35498 1/20 0.32
SCN5A Q14524 1/20 0.32
SCN8A Q9UQD0 1/20 0.32
HDAC6 Q9UBN7 1/20 0.31
SIGMAR1 Q99720 1/20 0.31
CTSL P07711 1/20 0.30
CTSB P07858 1/20 0.30
CTSS P25774 1/20 0.30
CTSK P43235 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25701645 1.00 TGFBR1 (0.38) TGFBR1PDPK1MAPK1TNIKALOX5AP
SCHEMBL31529538 0.90 TEAD1 (0.34) PIK3CD
SCHEMBL25703862 0.90 SCN1A (0.35) ALOX5APFEN1PIK3CDSCN1ASCN5A
SCHEMBL30438685 0.90 SCN1A (0.35) ALOX5APFEN1PIK3CDSCN1ASCN5A
SCHEMBL25702513 0.82 MOGAT2 (0.32) ALOX5APFEN1MOGAT2HDAC6CTSL
SCHEMBL30438919 0.82 MOGAT2 (0.32) ALOX5APFEN1MOGAT2HDAC6CTSL
SCHEMBL25437180 0.78 PIK3CA (0.40) ALOX5APFEN1MOGAT2SCN1ASCN5A
SCHEMBL31529481 0.78 PIK3CA (0.40) ALOX5APFEN1MOGAT2SCN1ASCN5A
SCHEMBL30438528 0.78 ALOX5AP (0.38) MAPK1ALOX5APFEN1MOGAT2CTSL
SCHEMBL30438715 0.78 ALOX5AP (0.33) ALOX5APFEN1MOGAT2NR3C1PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4436955-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS Lario Therapeutics Limited (GB) 2024-10-02 EP disclosed
WO-2023094830-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS LARIO THERAPEUTICS LIMITED (GB) 2023-06-01 WO disclosed